Ionis Pharmaceuticals releases information on their planned phase 3 clinical trial for Angelman syndrome
Ionis Pharmaceuticals announces ION582 will advance into Phase 3, called REVEAL, with details to be presented at the FAST Global Science Summit on November 9th.